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Increased stroke risk among chronic obstructive pulmonary disease patients has not yet been established. In this study,
we conducted a systematic review and meta-analysis to assess stroke risk among chronic obstructive pulmonary
disease patients. PubMed, EMBASE, and the Cochrane Library were systematically searched from database inception
until December 31, 2016 to identify longitudinal observational studies that investigated the association between
chronic obstructive pulmonary disease and stroke. Stroke risk was quantified by overall and subgroup analyses, and a
pooled hazard ratio was calculated. Study quality was evaluated using the Newcastle-Ottawa Scale. Publication bias
was assessed using Begg’s rank correlation test. Eight studies met the inclusion criteria. In a random-effects model,
significantly increased stroke risk was observed among chronic obstructive pulmonary disease patients (hazard ratio,
1.30; 95% confidence interval, 1.18-1.43). In subgroup analyses stratified by stroke subtype, study quality, and
adjustment by socioeconomic status, the association between increased stroke risk and chronic obstructive pulmonary
disease patients was robust. Statistically significant publication bias was not detected. In summary, chronic obstructive
pulmonary disease was found to be associated with increased stroke risk. Additional prospective studies are required
to elucidate the mechanisms underlying the increase in stroke risk and identify effective preventive interventions.
KEYWORDS: Cerebrovascular Disease; Chronic Obstructive Pulmonary Disease; Meta-Analysis; Stroke.
’ INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is character-
ized by persistent and usually progressive airflow restriction (1).
COPD may limit activity, compromise quality of life, and result
in disability. As such, this disorder presents a major, incurable
population health burden (2). In addition, COPD patients may
suffer from additional systemic manifestations of the disorder.
Comorbid medical conditions further contribute to disease
severity, functional impairment, reduced quality of life, and
poor clinical outcomes. Cardiovascular diseases (CVDs), includ-
ing ischemic heart disease, atrial fibrillation, and heart failure,
and cerebrovascular diseases are the most prevalent and fatal
comorbidities of COPD (3).
While the coexistence of COPD and CVD is well esta-
blished, whether COPD increases the individual’s risk for all
types of CVD has not been confirmed. Shared risk factors,
persistent inflammation, and vulnerability to infection have
been proposed as mechanisms by which COPD and CVD
might be linked (4). While there is evidence suggesting that
COPD increases the risk of heart disease (4,5), studies con-
ducted to date on the risk of stroke among COPD patients
have generated conflicting results. A recent review of the
current evidence on stroke risk among COPD patients was
limited by a dependence on cross-sectional data, which pre-
cluded a firm establishment of causality between COPD and
stroke (4).
To further investigate the relationship between COPD and
stroke, we performed the present meta-analysis of longitudinal
studies and evaluated incident stroke in COPD patient cohorts.
The primary aim of this study was to clarify whether COPD
patients are at increased risk of stroke. Secondary aims were
to assess whether the association between COPD and stroke
varies according to the type of stroke or the core adjusted vari-
ables, including socioeconomic status (SES). A systematic
review of the literature on the association between stroke and
COPD was undertaken in order to provide a comprehensive
perspective on disease mechanisms in COPD and to identify
potential strategies for stroke prevention among COPD patients.
’ METHODS
Search strategy
Three databases (PubMed, EMBASE, and the Cochrane
Library) were systematically searched from their inception to
December 31, 2016. The following search terms were usedDOI: 10.6061/clinics/2018/e177
Copyright & 2018 CLINICS – This is an Open Access article distributed under the
terms of the Creative Commons License (http://creativecommons.org/licenses/by/
4.0/) which permits unrestricted use, distribution, and reproduction in any
medium or format, provided the original work is properly cited.
No potential conflict of interest was reported.
Received for publication on May 16, 2017. Accepted for publication
on November 27, 2017
1
REVIEW ARTICLE
to identify potential studies for inclusion: (COPD OR chronic
obstructive airways disease OR chronic obstructive bronchial
disease OR emphysema OR chronic bronchitis) and (stroke
OR cerebrovascular disease OR cerebrovascular accident OR
cerebral ischemia OR ischemic stroke OR transient ischemic
accident OR hemorrhagic stroke). No search filters were
applied. We also identified additional papers by reviewing
the relevant articles listed in the references. This review
followed the meta-analysis of observational studies in
epidemiology (MOOSE) guidelines.
Study selection and inclusion criteria
Primary studies investigating stroke occurrence among
COPD patients were eligible for inclusion. Additional eligi-
bility criteria were that each study had to report the risk of
developing stroke (e.g., not stroke-related mortality) and
provide measures of association (hazard ratio (HR), incidence
ratio (IR), or odds ratio (OR)) and precision (confidence interval
(CI)). To investigate causality, we further narrowed the inclu-
sion criteria to include only observational studies using a
longitudinal study design. In the case of multiple publications
using the same study population, only the most recent, largest,
or most relevant publication was selected for inclusion.
Data extraction
Databases searches and data extraction were conducted
by two independent investigators (YRK and YJL). Disagree-
ments were resolved through consultation with a third author
(ICH). The following information was extracted from each
study: first author, year of publication, country, study setting,
study design, measures of association with the correspond-
ing 95% Cis, and core adjusted variables. Fully adjusted
measures of association were extracted from the included
studies. The Newcastle-Ottawa Scale, which is mainly based
on potential confounding variables in the study populations,
was used to assess methodological study quality.
Statistical analysis
This investigation aimed to assess whether there is an
increased risk of incident stroke among COPD patients com-
pared to control subjects. Subgroup analyses were performed
for stroke subtype (all types, ischemic stroke, or hemorrhagic
stroke); study quality (low or high); and consideration of SES
(unadjusted or adjusted). HRs (with 95% CIs) from the indi-
vidual studies were pooled. Using well-established methods (6)
for calculating the variance of log HR from each study,
we converted the 95% CIs to their natural logarithmic value
by dividing the range of the CI by 3.92. We used Higgins I2
(0-100%) to assess the heterogeneity across studies. When
substantial heterogeneity (I2X50%) was observed, we used
the DerSimonian and Laird random-effects model as pre-
viously described (7). Random-effects models attempt to
generalize findings beyond the included studies by assum-
ing that the selected studies are random samples from a
larger population (8). We also assessed publication bias using
Begg’s rank correlation test. Stata software (version 12.1,
StataCorp, College Station, TX, USA) was used for all stati-
stical analyses.
’ RESULTS
Figure 1 presents the flow diagram of the identification of
relevant studies. From the 3,048 articles that were initially
retrieved, 233 underwent abstract review, and 18 articles
underwent full-text review. Ten articles were subsequently
excluded for the following reasons: no relevant control group
(n=4); no separate estimate of COPD association with stroke
(n=4); or no estimates on exacerbated COPD (n=2). A total of
eight studies were included in the final analysis.
Characteristics of the included studies are summarized in
Table 1. Most studies were conducted in Western countries
(n=7) and investigated newly developed stroke (n=6). Only
one study utilized a prospective cohort design. The core
adjusted variables were metabolic comorbidities (hyperten-
sion, type 2 diabetes, and hyperlipidemia); prior CVD (ischemic
heart disease and stroke); lifestyle (cigarette smoking, alcohol
consumption, and obesity); and SES. Five recently published
studies were rated as high-quality studies.
Overall, a significantly increased risk of stroke was observed
among COPD patients (HR, 1.30; 95% CI, 1.18-1.43; po0.001;
Figure 2). No single study unduly impacted the results. The
association between COPD and stroke risk remained robust in
subgroup analyses by stroke subtype, study quality, and
adjustment for SES (Table 2). Interestingly, high-quality studies
and studies that adjusted for SES variables tended to have
smaller effect sizes. Funnel plot asymmetry among studies was
not observed (p=0.135; Figure 3).
’ DISCUSSION
As comorbidities may substantially influence the severity
and prognosis of COPD, studies exploring the associations
between specific comorbidities and COPD are urgently needed.
Stroke carries a significant risk of morbidity and mortality
and is one of the most common causes of death and severe
disability. Increased risk of stroke among COPD patients will
increase the burden on their caregivers, whom are prone to
adverse mental health when looking after COPD or stroke
patients (9,10). Stroke may also contribute to pulmonary
dysfunction due to impaired cough and/or weakness of
respiratory muscles, resulting in an increased propensity for
pneumonia (11). Accordingly, incident stroke in COPD can
accelerate and further increase mortality risk. In our pooled
analysis, COPD patients were found to have a 30% increased
risk of developing stroke compared with non-COPD sub-
jects. The observed association between COPD and stroke
risk remained robust in subgroup analyses by stroke subtype
and after adjustment for core variables. These results suggest
that stroke risk should be closely monitored and controlled
in patients with COPD.
Our subgroup analyses suggest that the increased stroke
risk among COPD patients is not merely due to confounding
by common risk factors, such as smoking, metabolic comor-
bidities, or SES. There is no doubt that cigarette smoking is
associated with an increased risk of CVD, including stroke,
and indeed, smoking has been shown to be associated with
preclinical brain changes on magnetic resonance imaging (12).
However, in prior studies of COPD and stroke, risk estimates
were reduced by only approximately 10% after adjusting for
smoking (13,14). In addition, cerebral small vessel disease has
been shown to be significantly more prevalent among smokers
with COPD than smokers without COPD (15), suggesting an
additional pathogenic effect of COPD beyond the harm from
smoking itself. Socioeconomic inequalities may also poten-
tially account for disparities among risk factors (16); however,
in our analysis, SES did not critically impact the observed
associations between COPD and increased stroke risk, which
supports the existence of a COPD-specific effect.
2
COPD and Stroke Risk
Kim YR et al.
CLINICS 2018;73:e177
Potential mechanisms by which COPD and stroke might be
linked include increased systemic inflammation (for example,
resulting in elevated interleukin-6 and C-reactive protein levels)
and increased oxidative stress (17). COPD is a persistent airway
inflammatory process and can potentially cause a continuous
spillover of inflammatory mediators from the lungs into the
blood stream (18). Many human studies have demonstrated
increased serum levels of inflammatory and oxidative stress
markers in COPD patients compared to controls (19,20). This
dispersion of pro-inflammatory factors from the lungs may
contribute to endothelial dysfunction and promote a pro-
coagulative state, which may then lead to atherothrombosis,
thereby providing a potential mechanistic link between COPD
and the increased risk of cerebrovascular events (18). Further-
more, pro-inflammatory cytokines, including interleukin-6 and
tumor necrosis factor alpha (TNF-a), were found to be elevated
in depression (21). Depression is a common comorbidity of
COPD (22) and stroke (23). This observation further strengthens
the neuro-immunological link among smoking, cardiovascular
risk factors, COPD and stroke (24). Furthermore, the incidence
rate of stroke has been found to be significantly increased
following acute COPD exacerbations (25,26). Such exacerba-
tions represent times of intense oxidative stress and increased
systemic inflammation (27). However, to date, no clinical data
have suggested that suppression of inflammation prevents or
improves CVD outcomes. For example, statin use was not
beneficial for COPD patients, and use of an inhaled corticoster-
oid was not found to affect cardiac mortality (28,29).
Another mechanism by which COPD may specifically
increase the risk of stroke is through hypoxemia. COPD patients,
particularly those with more advanced disease, may experi-
ence hypoxemia, and subsequent hyperventilation contributes
to vessel wall changes (30). Metabolic disturbances resulting
from hyperventilation may also induce cardiac arrhythmias.
Reduced lung function in COPD patients has been found to be
inversely associated with incident atrial fibrillation, another
condition that might predispose patients to stroke (31). COPD
represents more than impaired lung function, but reduced
lung capacity itself, regardless of the cause, has been asso-
ciated with increased risk of atrial fibrillation (32,33), stroke
(34,35) and CVD mortality (36).
In the current study, although the majority of stroke events
among COPD patients were of the ischemic type, the asso-
ciation between COPD and the risk of hemorrhagic stroke
was also robust. Levels of plasminogen activator inhibitor-1
(PAI-1), a major inhibitor of fibrinolysis, were found to be
higher in COPD patients and may contribute to thrombosis
and ischemic stroke among these patients (37). Plasminogen
activators were found to be beneficial for patients with mild
stroke (38). However, additional study is required to evaluate
the efficacy and safety of plasminogen activators as a treat-
ment for stroke among COPD patients. Some risk factors are
shared across all stroke subtypes, while others are differen-
tially related (39). Aging and smoking are known to disrupt
the blood-brain barrier (40,41), which may contribute to the
increased risk of hemorrhagic stroke among COPD patients.
High blood pressure is also a major risk factor for hemo-
rrhagic stroke (42), and accumulation of blood within the
brain may rapidly lead to damage due to mechanical injury
and increased pressure (43). Prevalent use of anticoagulant
Figure 1 - Flow diagram of the identification of relevant articles.
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therapy for arrhythmias (3) in COPD patients may also partly
explain the association between COPD and the increased risk
of hemorrhagic stroke.
The present study has some limitations, mainly regarding
study design, as it relied on data from studies using admini-
strative healthcare databases. When using administrative
Figure 2 - Forest plot showing the risk of stroke among COPD patients. HR, hazard ratio; and CI, confidence interval.
Table 2 - Risk of developing stroke among patients with COPD.
No. of studies Summary HR (95% CI) Heterogeneity, I2 Model
Stroke subtypes
All stroke (13,14,25,31,49-52) 8 1.30 (1.18-1.43) 82.4% Random-effects
Ischemic stroke (25,49,50) 3 1.31 (1.03-1.66) 94.0% Random-effects
Hemorrhagic stroke (25,49,50) 3 1.31 (1.20-1.43) 0% Fixed-effects
Study quality
Low (31,51,52) 3 1.32 (1.23-1.41) 0% Fixed-effects
High (13,14,25,49,50) 5 1.28 (1.10-1.50) 89.3% Random-effects
SES variables
Unadjusted (13,25,31,50-52) 6 1.30 (1.14-1.49) 82.5% Random-effects
Adjusted (14,49) 2 1.24 (1.20-1.29) 0% Fixed-effects
COPD, chronic obstructive pulmonary disease; SES, socioeconomic status; HR, hazard ratio; and CI, confidence interval.
Figure 3 - Begg’s funnel plot for incident stroke among the included studies (p=0.135). HR, hazard ratio.
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healthcare data, there exists uncertainty regarding the dia-
gnoses of COPD and stroke; healthcare databases usually do
not contain records of lung function tests and brain imaging
studies. Records from these sources also lack information on
several important characteristics, including lifestyle factors
such as smoking status, alcohol consumption, and physical
and sedentary activity, thus preventing further stratified
analyses. Variation among adjusted variables might partially
account for the high heterogeneity found in the current meta-
analysis. Another limitation of the included studies was that
there was insufficient information on medication effects.
COPD patients frequently use medications that may induce
an acute CVD episode, including anticholinergic agents and
sympathomimetic medications (44,45). COPD patients may
also require treatment with macrolides and quinolone
antibiotics, which are both associated with increased risk of
adverse cardiovascular side effects (46). Finally, in this meta-
analysis, there were not enough studies from non-Western
countries, such as Asian studies. Further research is required
to study the risk of stoke among Asian patients with COPD.
At present, there are reports that Asian patients with COPD
and stroke are more likely to report negative health and
functional status (47). To further clarify the relationship
between COPD and stroke risk, well-designed, prospective
cohort studies with collaborating interventional trials are
required. Further basic science studies are also required to
explore whether targeting oxidative stress and lung and
systemic inflammatory pathways may provide effective
approaches for preventing vascular injury.
In conclusion, the results of this study suggest that COPD
increases the risk of stroke, independent of other shared
CVD risk factors. Current knowledge on the most effective
approach for reducing stroke risk in COPD patients is still
limited. For example, anticoagulant therapy is indicated only
for COPD patients with atrial fibrillation (48). Primary care
physicians should pay close attention to CVD risk, including
stroke risk, from the time of COPD diagnosis, and where
appropriate, they should work more closely with cardio-
logists and neurologists to enable optimal vascular care for
patients with COPD.
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